<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544462</url>
  </required_header>
  <id_info>
    <org_study_id>Genomic Prediction Inc 625</org_study_id>
    <nct_id>NCT04544462</nct_id>
  </id_info>
  <brief_title>ANXA5 M2 Haplotyping in IVF Patients and Embryos</brief_title>
  <official_title>ANXA5 M2 Haplotyping in IVF Patients and Embryos</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genomic Prediction Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genomic Prediction Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to characterize the association between history of pregnancy complications&#xD;
      and M2 carrier status in IVF patients and the utility of M2 haplotype preimplantation genetic&#xD;
      testing (PGT) in embryos produced by carrier couples. Participants in this study will be&#xD;
      screened for the M2 variant. History of pregnancy complications and miscarriages will be&#xD;
      studied in order to determine potential associations with M2 carrier-ship.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients consenting to participation in the study will receive a saliva collection kit for M2&#xD;
      testing. Genomic Prediction Clinical Laboratory will perform testing and issue a report per&#xD;
      routine clinical procedures. Upon completion of issuing a report, the patients' medical&#xD;
      records will be obtained from the IVF Center providing care to the patient. Information&#xD;
      obtained may include: history of miscarriage, embryo transfer outcomes, preeclampsia, small&#xD;
      for gestation age baby, or thrombophilia disorders.&#xD;
&#xD;
      In addition to obtaining records related to history of pregnancy complications, carrier&#xD;
      couples will be offered the use of preimplantation genetic testing for M2 carrier status&#xD;
      (PGT-M2) in their embryos. Patients electing to perform PGT-M2 will receive PGT-A according&#xD;
      to standard clinical practice, along with M2 carrier status.&#xD;
&#xD;
      A total of 500 patients will complete the study and may be recruited from any IVF clinic in&#xD;
      the United States. Patients will undergo ovarian hyper-stimulation, oocyte retrieval,&#xD;
      fertilization and embryo culture per standard clinical protocol determined by each clinic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>M2 Haplotype frequency</measure>
    <time_frame>1 month</time_frame>
    <description>Frequency of carriers of the M2 haplotype attending an IVF center for infertility treatment.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Infertility</condition>
  <condition>Miscarriage, Recurrent</condition>
  <condition>Pregnancy Complications</condition>
  <arm_group>
    <arm_group_label>Infertile patients</arm_group_label>
    <description>Patients attending an IVF center for infertility treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>M2 Test</intervention_name>
    <description>DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.</description>
    <arm_group_label>Infertile patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva swabs will be collected from participants. DNA will be extracted and used to screen&#xD;
      for the M2 haplotype.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All couples above the age of 18 seeking infertility treatment at IVF centers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All couples above the age of 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any case where biological parental DNA is unavailable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nathan Treff, PhD</last_name>
    <phone>(973) 529-4223</phone>
    <email>clinicaltrials@genomicprediction.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diego Marin, PhD</last_name>
    <phone>(973) 529-4223</phone>
    <email>clinicaltrials@genomicprediction.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Genomic Prediction Clinical Laboratory</name>
      <address>
        <city>North Brunswick</city>
        <state>New Jersey</state>
        <zip>08902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Duffy, BA</last_name>
      <phone>973-529-4223</phone>
      <email>leslie@genomicprediction.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

